GLP-1R agonists therapy for type 2 diabetes
| Autor: | Hao Gong, Bilan Zhou, Anlin Peng, Kun Huang |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
endocrine system
Multidisciplinary Mechanism (biology) business.industry Potential risk digestive oral and skin physiology Type 2 Diabetes Mellitus Type 2 diabetes Hypoglycemia medicine.disease Bioinformatics medicine Signal transduction business Receptor Beneficial effects hormones hormone substitutes and hormone antagonists |
| Zdroj: | Wuhan University Journal of Natural Sciences. 19:27-33 |
| ISSN: | 1993-4998 1007-1202 |
| Popis: | Glucagon-like peptide-1 receptor (GLP-1R) agonists are widely used for treating type 2 diabetes mellitus (T2DM) because of their glucose-lowering and weight-losing effects, and low risk of hypoglycemia. Hence, there is considerable interest in understanding the mechanism underlying the beneficial effects of GLP-1 and developing stable and effective GLP-1R agonists. Here, we summarize the presently known mechanism of GLP-1 actions, which are mainly through regulating cAMP-PKA signaling pathway; the latest developments in novel clinical GLP-1R agonists are also introduced, which are characterized with multiple properties, such as extended half-life, reduced side-effects, lower production costs and more convenient drug dosing mode. The potential risk of GLP-1-based therapeutics, an often-ignored fact, is also discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink